+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Feasibility study of postoperative adjuvant chemotherapy and radiotherapy for soft-tissue sarcoma

Feasibility study of postoperative adjuvant chemotherapy and radiotherapy for soft-tissue sarcoma

Cancer ChemoTherapy and Pharmacology 31(Suppl. 2): S199

In a nonrandomized trial, postoperative, adjuvant, combined chemotherapy and radiotherapy were given to 17 patients with high-grade soft-tissue sarcomas. All patients had undergone conservative limb-sparing surgery. Soft-tissue sarcomas were localized in the extremities (13 patients), superficial trunk (3), and neck (1). In all, 13 patients received 50 mg/m2 doxorubicin and 5 g/m2 ifosfamide with mesna uroprotection for a total of 6 cycles and 4 patients received CYVADIC (cyclophosphamide/vincristine/doxorubicin/dacarbazine). Chemotherapy was started immediately after wound healing. Irradiation using the shrinking-field technique was commenced 3-7 days following chemotherapy; a total dose of 65 Gy was applied. The major side effects of chemotherapy were nausea and vomiting [17 of 17 patients, 5 experiencing World Health Organization (WHO) grade 3 toxicity and 1, WHO grade 4], leukopenia of <3.0 x 10(9)/l (17 patients), and leukopenia of <1.0 x 10(9)/l (7 patients). The median leukocyte nadir was reached on day 11 (range, days 7-16). The duration of critical leukopenia did not exceed 1 week. Reversible alopecia occurred in all patients. Temporary cardiomyopathy was recorded in 1 patient. Following radiotherapy, 11 episodes of epitheliolysis and 1 case of moderate lymphedema were documented. There was no life-threatening condition. After a follow-up of 58 months, the outcome was as follows: disease-free survival, 9 patients; distant metastases, 7; local recurrence, 1. Excluding 3 patients who entered the study after undergoing surgery for local relapse, the rate of distant metastases was 36%. In summary, the postoperative use of chemotherapy/radiotherapy is feasible, producing relevant but manageable toxicity. This combination results in effective local tumor control with good functional results following limb-sparing surgery. The incidence of distant metastases, however, is high.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 031430410

Download citation: RISBibTeXText

PMID: 8453698

Related references

Significant improvement of relapse free survival as well as time to distant failure for adult grade 3 soft tissue sarcoma after adjuvant augmented chemotherapy plus adjuvant hyperfractionated accelerated radiotherapy A prospective randomized trial of the Austrian cooperative soft tissue sarcoma study group. European Journal of Cancer 35(Suppl. 4): S269-S270, 1999

Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX). European Journal of Cancer 99: 78-85, 2018

Intensified adjuvant IFADIC chemotherapy in combination with radiotherapy versus radiotherapy alone for soft tissue sarcoma: long-term follow-up of a prospective randomized feasibility trial. Wiener Klinische Wochenschrift 122(21-22): 614-619, 2010

Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma. Journal of the National Cancer Institute 67(6): 1213-1218, 1981

Five-year results from a Scandinavian sarcoma group study (SSG XIII) of adjuvant chemotherapy combined with accelerated radiotherapy in high-risk soft tissue sarcoma of extremities and trunk wall. International Journal of Radiation Oncology Biology Physics 81(5): 1359-1366, 2011

A phase II study evaluating neo-/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma. Bmc Cancer 11: 510, 2011

Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Journal of Clinical Oncology 12(6): 1137-1149, 1994

Adjuvant chemotherapy-Radiotherapy-Chemotherapy sandwich protocol in resectable soft tissue sarcoma: An updated single-center analysis of 104 cases. Plos one 13(5): E0197315, 2018

Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma. Tumori 104(5): 322-329, 2018

Combined chemotherapy and radiotherapy as postoperative adjuvant treatment in soft tissue sarcomas. Journal of Cancer Research and Clinical Oncology 116(Suppl. Part 1): 586, 1990

Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma 4(4): 151-160, 2000

EP-1399: Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma. RadioTherapy and Oncology 119: S652-S653, 2016

Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer 73(6): 1644-1651, 1994

Adjuvant chemotherapy in early soft tissue sarcoma and palliative chemotherapy in advanced soft tissue sarcoma in adults. Praxis 87(34): 1066-1071, 1998

A randomized prospective trial using postoperative adjuvant chemotherapy (adriamycin) in high-grade extremity soft-tissue sarcoma. American Journal of Clinical Oncology 11(1): 39-45, 1988